Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study
PR Newswire —
JUNO BEACH, Fla., Dec. 22, 2025 /PRNewswire/ -- Aqualung Therapeutics, a clinical-stage immunotherapeutics company, announced today that the Food and Drug Administration (FDA) has cleared its Phase 2a study of ALT-100 mAb as an anti-inflammatory and anti-fibrotic therapy in human subjects...